Biotech Values

[DewDiligence]

The Long Fat HCV Tail may finally have arrived:

Actually, there was no QoQ decline, which is pretty significant, IMO.https://t.co/eCy1D3sRTn

— Roy Friedman (@DewDiligence) May 2, 2019

https://twitter.com/Howlinghamster/status/1124048571454586881

One quarter isn't enough data to be sure, of course. ABBV's 1Q19 HCV sales of $815M were inline with ABBV's 2019 guidance of $3.3B, but GILD's 1Q19 HCV sales of $790M were $90M above the midpoint of GILD's 2019 guidance range of $2.7-2.9B (which was reiterated yesterday), suggesting that subsequent quarters could be somewhat lighter.